These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 19516186)

  • 1. Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study.
    Krum H; Swergold G; Curtis SP; Kaur A; Wang H; Smugar SS; Weir MR; Laine L; Brater DC; Cannon CP
    J Hypertens; 2009 Apr; 27(4):886-93. PubMed ID: 19516186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Cannon CP; Curtis SP; FitzGerald GA; Krum H; Kaur A; Bolognese JA; Reicin AS; Bombardier C; Weinblatt ME; van der Heijde D; Erdmann E; Laine L;
    Lancet; 2006 Nov; 368(9549):1771-81. PubMed ID: 17113426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NSAID-antihypertensive drug interactions: which outpatients are at risk for a rise in systolic blood pressure?
    Floor-Schreudering A; De Smet PA; Buurma H; Kramers C; Tromp PC; Belitser SV; Bouvy ML
    Eur J Prev Cardiol; 2015 Jan; 22(1):91-9. PubMed ID: 24042856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Laine L; Curtis SP; Cryer B; Kaur A; Cannon CP;
    Lancet; 2007 Feb; 369(9560):465-73. PubMed ID: 17292766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugs.
    Krum H; Swergold G; Gammaitoni A; Peloso PM; Smugar SS; Curtis SP; Brater DC; Wang H; Kaur A; Laine L; Weir MR; Cannon CP
    Cardiovasc Ther; 2012 Dec; 30(6):342-50. PubMed ID: 21884017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program.
    Krum H; Curtis SP; Kaur A; Wang H; Smugar SS; Weir MR; Laine L; Brater DC; Cannon CP
    Eur J Heart Fail; 2009 Jun; 11(6):542-50. PubMed ID: 19380329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis.
    Cannon CP; Curtis SP; Bolognese JA; Laine L;
    Am Heart J; 2006 Aug; 152(2):237-45. PubMed ID: 16875903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparative evaluation of the safety and efficacy of etoricoxib and diclofenac on the upper gastrointestinal tract in patients with osteoarthrosis and rheumatoid arthritis (the multinational etoricoxib and diclofenac arthritis long-term (MEDAL) study program)].
    Alekseeva LI
    Ter Arkh; 2010; 82(8):57-62. PubMed ID: 20873248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial.
    Baraf HS; Fuentealba C; Greenwald M; Brzezicki J; O'Brien K; Soffer B; Polis A; Bird S; Kaur A; Curtis SP;
    J Rheumatol; 2007 Feb; 34(2):408-20. PubMed ID: 17304660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis.
    Feng X; Tian M; Zhang W; Mei H
    PLoS One; 2018; 13(1):e0190798. PubMed ID: 29320568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).
    Krueger K; Lino L; Dore R; Radominski S; Zhang Y; Kaur A; Simpson R; Curtis S
    Ann Rheum Dis; 2008 Mar; 67(3):315-22. PubMed ID: 17965424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac.
    Laine L; Curtis SP; Langman M; Jensen DM; Cryer B; Kaur A; Cannon CP
    Gastroenterology; 2008 Nov; 135(5):1517-25. PubMed ID: 18823986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study).
    Combe B; Swergold G; McLay J; McCarthy T; Zerbini C; Emery P; Connors L; Kaur A; Curtis S; Laine L; Cannon CP
    Rheumatology (Oxford); 2009 Apr; 48(4):425-32. PubMed ID: 19223284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib.
    Curtis SP; Ko AT; Bolognese JA; Cavanaugh PF; Reicin AS
    Curr Med Res Opin; 2006 Dec; 22(12):2365-74. PubMed ID: 17265571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
    Prescrire Int; 2007 Dec; 16(92):223-7. PubMed ID: 18084859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [By what means does the rheumatic patient with gastrointestinal risks fare best?].
    Einecke D
    MMW Fortschr Med; 2007 Mar; 149(10):18. PubMed ID: 17408040
    [No Abstract]   [Full Text] [Related]  

  • 17. How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial.
    Laine L; Goldkind L; Curtis SP; Connors LG; Yanqiong Z; Cannon CP
    Am J Gastroenterol; 2009 Feb; 104(2):356-62. PubMed ID: 19174782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [3 questions about gastrointestinal risk. Are coxibs here clearly better than NSAID?]].
    Krüger K
    MMW Fortschr Med; 2006 Nov; 148(48):12. PubMed ID: 17615761
    [No Abstract]   [Full Text] [Related]  

  • 19. [Effect of nonsteroidal anti-inflammatory drugs on the indicators of cardiovascular risk in patients with acute nonspecific back pain].
    Zolotovskaya IA; Davydkin IL
    Ter Arkh; 2015; 87(12):18-25. PubMed ID: 26978413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial.
    Ruschitzka F; Borer JS; Krum H; Flammer AJ; Yeomans ND; Libby P; Lüscher TF; Solomon DH; Husni ME; Graham DY; Davey DA; Wisniewski LM; Menon V; Fayyad R; Beckerman B; Iorga D; Lincoff AM; Nissen SE
    Eur Heart J; 2017 Nov; 38(44):3282-3292. PubMed ID: 29020251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.